Dasatinib is an FDA-approved inhibitor of SFKs, with additional inhibition of BCR-ABL [27] [28], and is used for treatment of chronic myelogenous leukemia [29]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.